Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2025-03-28 Governance Information
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力总经理工作细则（2025年3月修订）
Governance Information Classification · 95% confidence The document is titled '总经理工作细则' (General Manager Work Rules) and details the responsibilities, authority, and operational procedures for the company's general manager and senior management. It includes governance and management structure, reporting duties, meeting protocols, and information disclosure requirements. There is no indication that this is a financial report, audit, earnings release, or any regulatory filing related to financial results or capital markets. Instead, it is a governance and management internal rules document. Therefore, the most appropriate classification is Governance Information (CGR). The document length (4820 characters) and content confirm it is a detailed governance policy rather than an announcement or summary.
2025-03-28 Chinese
天士力关于召开2025年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2025 first extraordinary general meeting (临时股东大会) of the company TianShiLi Pharmaceutical Group Co., Ltd. It includes information about the meeting date, voting methods, agenda items (such as amendments to the articles of association and election of board members and supervisors), voting procedures, and attendance requirements. The document is not a report of voting results, nor is it a presentation or financial report. It is a formal announcement and notification to shareholders about the upcoming shareholders' meeting and related procedural details. This matches the definition of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-03-28 Chinese
天士力关于增补部分董事、监事的公告
Board/Management Information Classification · 100% confidence The document is an announcement from TianShiLi Pharmaceutical Group Co., Ltd. regarding the nomination and addition of certain directors and supervisors to the company's board and supervisory committee. It details the resignation of some board members, the nomination of new non-independent and independent directors, and the nomination of non-employee supervisors. The document includes candidate resumes and mentions the upcoming shareholder meeting where these nominations will be voted on. There is no financial data, earnings information, or audit content. The focus is on changes in the company's board and management structure. Therefore, this document fits the category of Board/Management Information (MANG). The document length is about 4889 characters, which is sufficient for a full announcement rather than a brief notice or report publication announcement.
2025-03-28 Chinese
天士力关于修订《公司章程》的公告
Governance Information Classification · 95% confidence The document is an announcement regarding the revision of the company's Articles of Association (公司章程). It details specific amendments to governance structures, responsibilities, and procedures within the company, including board and management roles, party organization, and approval processes. The document is issued by the company's board and is intended to be submitted for shareholder approval at an upcoming extraordinary general meeting. It is not a full annual or interim financial report, nor is it a transcript, audit report, or earnings release. It is a governance-related announcement about changes to the company's internal rules and governance practices. Therefore, it fits the category of Governance Information (CGR). The document length (7527 characters) and content support that it is a substantive governance report rather than a brief announcement or regulatory filing.
2025-03-28 Chinese
天士力公司章程（2025年3月修订）
Governance Information Classification · 100% confidence The document is titled "天士力医药集团股份有限公司 章程" which translates to "Articles of Association" or "Company Bylaws" of Tasly Pharmaceutical Group Co., Ltd. It contains detailed chapters about the company's organizational structure, shareholder rights, board of directors, management, financial accounting system, profit distribution, audit, and other governance-related matters. The content is focused on the internal rules, governance structure, shareholder meetings, and company operations rather than financial results or announcements. There is no indication that this is an annual report, audit report, earnings release, or any other financial or regulatory filing. It is a governance document outlining the company's internal rules and procedures. Therefore, the appropriate classification is Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full text of the governance document, not just an announcement or summary.
2025-03-28 Chinese
天士力第九届董事会第7次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 7th meeting of the 9th Board of Directors of the company. It details the meeting date, attendance, and voting results on various board matters such as nomination of directors, appointment of senior management, amendments to company bylaws, and notice of an upcoming shareholders meeting. It references other announcements for detailed content but itself serves as a summary of board decisions and voting outcomes. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management. The document length is short and it is not a full report or financial statement, so it is not an Annual Report or Interim Report. It is not a voting results declaration (DVA) because it covers multiple board resolutions, not shareholder vote results. Therefore, the best classification is MANG with high confidence.
2025-03-28 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.